BRUNOL4 Blocking Peptide
- Known as:
- BRUNOL4 Blocking Peptide
- Catalog number:
- 33r-7218
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Fitzgerald industries international
- Gene target:
- BRUNOL4 Blocking Peptide
Related genes to: BRUNOL4 Blocking Peptide
- Gene:
- CELF4 NIH gene
- Name:
- CUGBP Elav-like family member 4
- Previous symbol:
- BRUNOL4
- Synonyms:
- -
- Chromosome:
- 18q12.2
- Locus Type:
- gene with protein product
- Date approved:
- 2000-11-28
- Date modifiied:
- 2017-01-20
Related products to: BRUNOL4 Blocking Peptide
Related articles to: BRUNOL4 Blocking Peptide
- To explore hypermethylated gene markers in cervical scraped cells that may be associated with endometrial cancer and validate their diagnostic role in endometrial cancer. - Source: PubMed
Publication date: 2026/06/19
Chen XiaojingLiu LixinJin XitongCheng YananWu HuanwenYou YanLiou YulighLiu PeiLang JingheLi Lei - To address the growing incidence of endometrial cancer (EC), noninvasive detection methods are needed. Although self-sampling is proven for cervical cancer screening, its utility for EC detection via methylation analysis lacks robust evidence. This study aimed to validate this approach by evaluating the concordance and diagnostic accuracy of / methylation testing in self-collected samples compared with clinician-collected samples. - Source: PubMed
Publication date: 2026/06/18
He PeixuanWang YishanXie NianLiu ChengniangLiu PeiWang LinhaiYin SuyueZhou ShunxianCai HaiyiFu Chun - The increasing global incidence of endometrial cancer (EC) underscores the urgent need for effective early detection. Noninvasive detection approaches, such as transvaginal ultrasonography (TVS), frequently exhibit low specificity, leading to a high rate of unnecessary invasive procedures. DNA methylation analysis has emerged as a promising noninvasive alternative. This study aimed to validate gene methylation analysis for detecting endometrial intraepithelial neoplasia (EIN) and EC and, critically, to compare its diagnostic efficacy using noninvasive cervical brushing cells (CBCs) vs. invasive diagnostic curettage (D&C) samples. - Source: PubMed
Publication date: 2026/05/29
Cai BingxinWang YishanMa WenWu ZhenzhenYao TingtingLiu PeiWang LinhaiZhou PingpingLi Yilin - To evaluate the association between di(2-ethylhexyl) phthalate (DEHP) exposure and testosterone deficiency in adult men, and to explore molecular changes and candidate compounds related to DEHP-associated male reproductive toxicity. - Source: PubMed
Publication date: 2026/06/04
Gong ZhuozhiFeng QiujianChen WenyuXu ChengTang SiyuanLiu Shengjing - Despite significant advancements, the mechanisms underlying neuropathic pain remain poorly understood, making it challenging for effective pain management. This study investigated the role of CUGBP Elav-Like Family Member 4 (CELF4), an RNA-binding protein, in modulating pain pathways in neuropathic pain conditions. The results showed a reduction in both mRNA and protein levels of CELF4 in the spinal cord of a chronic constriction injury (CCI) mouse model, suggesting its potential role in response to nerve injury. To further explore the role of CELF4 in modulating pain pathways in vivo, an adeno-associated virus (AAV) was injected into mice to overexpress CELF4. The mice overexpressing CELF4 showed reduced hypersensitivity to mechanical and thermal stimuli as compared to controls, indicating effective mitigation of neuropathic pain symptoms. Mechanistically, the overexpression of CELF4 significantly downregulated the expressions of Transient Receptor Potential Vanilloid-1 (TRPV1) and Cyclooxygenase-2 (COX2), which are crucial mediators of pain signaling. In contrast, the knockdown of CELF4 rescued the TRPV and COX2 expressions, indicating that CELF4 might act as a suppressive regulator in neuropathic pain pathways. These results suggested that CELF4 played a critical role in regulating neuropathic pain by modulating specific ion channels and inflammatory markers, thus offering potential targets for therapeutic intervention in pain management. - Source: PubMed
Publication date: 2026/05/28
Kong GuanxiangTan RuiZeng XianmingZhang HailongZhang BinYu JiashengXie Rushan